Latest news with #biologicalintelligence
National Post
2 days ago
- Business
- National Post
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a company operating at the convergence of TechBio and biological intelligence, today announced that it has received formal notification from The Nasdaq Stock Market LLC ('Nasdaq') confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement. Article content The notice, dated July 11, 2025, stated that for the 10 consecutive business days from June 26, 2025, through July 10, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, ImmunoPrecise has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now closed. Article content Article content 'This compliance milestone reflects the growing recognition of our evolution into a platform company built around bio-native AI,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We're building the digital infrastructure that connects biological complexity with real-world impact – enabling new possibilities in therapeutic development and beyond. The recent momentum in our share price is a strong signal of support for that vision.' Article content Through its proprietary LENS ai™ platform powered by HYFT ® technology, ImmunoPrecise is reimagining how biological data can be modeled and deployed at scale. The LENS ai platform is transforming therapeutic discovery from a decades-long process to rapid, precision-guided development by systematically identifying the most promising therapeutic pathways through integration of sequence, structure, literature and functional data across the entire biosphere. Article content Our integrated framework enables unprecedented zero-shot discovery scenarios where LENS ai predicts therapeutic interactions for completely novel targets, demonstrated through recent validation across 17 previously unseen antibody-protein complexes, achieving near-crystallography precision without prior training data. This unique bio-native AI approach captures functional meaning rather than structural patterns, enabling new capabilities across R&D from drug and vaccine discovery to systems biology and positioning IPA at the frontier of TechBio innovation. Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT ® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the Company's strategic direction, the Company's future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. Article content Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in AI and biotechnology; and other risks inherent to the Company's industry and business model. Article content Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Article content Article content Article content Article content Article content Article content Article content
Associated Press
03-07-2025
- Business
- Associated Press
Olga Osokina Named Innovation Leader of the Year at the Global Innovation Online Awards 2025
07/03/2025, Las Vegas, NV // KISS PR Brand Story PressWire // The inaugural edition of the Global Innovation Online Awards 2025, hosted by has concluded with a celebration of the world's most forward-thinking leaders and groundbreaking achievements in technology, science, and business. In a competitive field of over 2500 international nominees, Olga Osokina has been named Innovation Leader of the Year for her exceptional contributions to the intersection of biological intelligence, artificial intelligence, and enterprise transformation. The award recognizes individuals whose work is redefining innovation on a global scale. 'Olga represents the future of intelligent growth — where human biology and machine learning are not separate paths, but one powerful system,' said the organizing committee. The Innovation Leader of the Year award is selected through a multi-stage review process conducted by an independent international panel of experts in technology, academia, and venture capital. Judges are rotated annually and have no affiliation with nominees. The process is confidential and merit-based. Olga Osokina is recognized globally as a trailblazer in innovation. As the CEO of UME Tech, a respected Forbes Lister, multi-award winner, and Chair of the Judging Committee at the International Business Awards, she brings a rare combination of strategic depth and future-ready vision. She also serves as a judge at the CES Innovation Awards and is a sought-after speaker at international conferences. Her innovation strategy frameworks have helped generate over $30 million in client revenue and enabled growth in more than 18 countries. She has advised organizations ranging from AI startups to Fortune 500 enterprises, integrating biological systems thinking with machine-driven marketing and product innovation. 'Innovation today is not about tools — it's about integration, intelligence, and impact,' Olga said during her acceptance remarks. is an independent international recognition platform supported by global thought leaders and strategic partners. The 2025 edition brought together hundreds of executives, researchers, founders, and creatives in a global digital celebration of progress — proving that borders no longer limit brilliance. Other 2025 honorees include leading innovators from MIT Media Lab, OpenAI, and the Global Innovators Community of the World Economic Forum. Global Luminary (Glonary) Awards Patrick Bovis [email protected] +1(310)9824241
